Literature DB >> 3893773

13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer.

F L Meyskens, G E Goodman, D S Alberts.   

Abstract

Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology has been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893773     DOI: 10.1016/s1040-8428(85)80040-8

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Authors:  Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

2.  Induction of differentiation of human promyelocytic leukemia cell line HL-60 by retinoyl glucuronide, a biologically active metabolite of vitamin A.

Authors:  M H Zile; M E Cullum; R U Simpson; A B Barua; D A Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial.

Authors:  S M Lippman; J F Kessler; M Al-Sarraf; D S Alberts; L M Itri; D Mattox; D D Von Hoff; L Loescher; F L Meyskens
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

4.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

5.  Cyclin D1 and cancer development in laryngeal premalignancy patients.

Authors:  Vassiliki Papadimitrakopoulou; Julie G Izzo; Diane D Liu; Jeffrey Myers; Tania L Ceron; Jan Lewin; William N William; Anthea Atwell; J Jack Lee; Ann Gillenwater; Adel El-Naggar; Xifeng Wu; Scott M Lippman; Walter N Hittelman; Waun Ki Hong
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

6.  Retinoid protection against x-ray-induced chromatid damage in human peripheral blood lymphocytes.

Authors:  K K Sanford; R Parshad; F M Price; R E Tarone; K H Kraemer
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 7.  Clinical pharmacokinetics of the retinoids.

Authors:  R W Lucek; W A Colburn
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

8.  Positive impact of retinyl palmitate in leukoplakia of the larynx.

Authors:  W J Issing; R Struck; A Naumann
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 3.236

9.  Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia.

Authors:  K Takitani; H Tamai; T Morinobu; N Kawamura; M Miyake; T Fujimoto; M Mino
Journal:  Jpn J Cancer Res       Date:  1995-04

Review 10.  Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  Cancers (Basel)       Date:  2017-08-31       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.